What is Zacks Research's Forecast for CORT Q2 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Research analysts at Zacks Research increased their Q2 2025 EPS estimates for Corcept Therapeutics in a report issued on Wednesday, March 19th. Zacks Research analyst K. Das now anticipates that the biotechnology company will earn $0.37 per share for the quarter, up from their prior estimate of $0.34. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics' Q3 2025 earnings at $0.47 EPS, FY2025 earnings at $1.64 EPS, Q2 2026 earnings at $0.67 EPS, Q3 2026 earnings at $0.82 EPS, Q4 2026 earnings at $0.89 EPS, FY2026 earnings at $2.83 EPS and FY2027 earnings at $3.81 EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.11). The company had revenue of $181.89 million during the quarter, compared to analyst estimates of $200.12 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%.

Several other research firms also recently commented on CORT. HC Wainwright reiterated a "buy" rating and issued a $115.00 target price on shares of Corcept Therapeutics in a research report on Thursday, February 27th. StockNews.com downgraded shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Canaccord Genuity Group upped their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a "buy" rating in a research report on Thursday, January 30th. Finally, Piper Sandler raised their price target on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $99.75.

Remove Ads

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT traded down $1.15 during mid-day trading on Friday, hitting $58.32. 663,487 shares of the stock traded hands, compared to its average volume of 971,763. The company has a market cap of $6.15 billion, a PE ratio of 46.29 and a beta of 0.61. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $75.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The firm has a 50 day simple moving average of $61.79 and a two-hundred day simple moving average of $54.29.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Corcept Therapeutics by 50.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 7,724 shares of the biotechnology company's stock valued at $389,000 after acquiring an additional 2,578 shares in the last quarter. Cache Advisors LLC acquired a new stake in Corcept Therapeutics in the 4th quarter valued at $378,000. Public Employees Retirement System of Ohio increased its stake in Corcept Therapeutics by 269.9% during the 4th quarter. Public Employees Retirement System of Ohio now owns 2,859 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 2,086 shares in the last quarter. Vise Technologies Inc. acquired a new position in Corcept Therapeutics during the fourth quarter worth $204,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Corcept Therapeutics by 11.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 224,713 shares of the biotechnology company's stock valued at $11,323,000 after buying an additional 22,361 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction on Friday, January 10th. The shares were sold at an average price of $50.54, for a total transaction of $111,188.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Sean Maduck sold 20,000 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the completion of the sale, the insider now owns 85,318 shares of the company's stock, valued at approximately $4,299,174.02. This represents a 18.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 45,627 shares of company stock worth $2,557,674 over the last ninety days. Insiders own 20.50% of the company's stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.